Recent Updates — OBIO

Orchestra BioMed Holdings, Inc. announced that its BACKBEAT Global Pivotal Trial of AVIM Therapy has exceeded enrollment targets, with 330 patients randomized as of September 30, 2026, surpassing the protocol-specified target of 316 patients across 81 sites in 13 countries. The trial evaluates Atrioventricular Interval Modulation Therapy for pacemaker-indicated patients with uncontrolled hypertension and is conducted in collaboration with Medtronic plc. Primary endpoint data are expected to be submitted for presentation at a major cardiovascular conference in the second quarter of 2027, potentially supporting future regulatory marketing applications by Medtronic. Orchestra BioMed Holdings, Inc. operates in the biomedical device industry, developing bioelectronic therapies and drug delivery systems through strategic partnerships with medical device companies.